Compare Expedia Group Inc (EXPE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Johnson & Johnson — how do they compare? Expedia Group Inc trades at $266.44 (market cap $32.06B), while Johnson & Johnson trades at $251.61 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 18.5× Expedia Group Inc's market cap, and Johnson & Johnson pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| EXPE | JNJ | |
|---|---|---|
Market Cap | $32.06B | $594.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $267.24 |
52-Week Low | $178.06 | $162.98 |
Enterprise Value | $30.97B | $627.57B |
Dividend Yield | 0.66% | 2.17% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $266.28, showing modest daily gains of 0.24%. The stock exhibits a bullish technical signal, supported by strong earnings beats in recent quarters and robust revenue growth from $11.7B in 2022 to $14.7B in 2025. The company maintains high profitability with a 90.27% gross margin and recently announced a strategic partnership with Allegiant Travel Company, expanding its online travel agency network.
The investment outlook is positive with analyst consensus at $292.09, representing 9.7% upside potential. Key opportunities include continued travel sector growth and operational efficiency gains from recent technology investments. Primary risks involve macroeconomic sensitivity affecting travel demand and competitive pressures in the online travel market. The company's strong cash flow generation supports shareholder returns through dividends and potential buybacks.
Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.
JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
